Liquid formulation comprising cetuximab and a fatty acid ester of polyoxyethylene sorbitan

本发明涉及包含西妥昔单抗(Cetuximab#+[�])的稳定的液体药物制剂，所述Cetuximab#+[�]是一种抗表皮生长因子受体(EGF受体)的嵌合单克隆抗体。所述制剂的贮藏稳定性增强并且可经胃肠外途径用于治疗肿瘤。 The invention relates to a stable liquid pharmaceutical formulation comprising Cetuximab(R), a chimeric monoclonal antibody against the receptor of endothelial growth factor (EGF receptor)...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	H.C. MAHLER, R. MILLER, U. MARTINI-MARR
Format:	Patent
Sprache:	chi ; eng
Schlagworte:	CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	本发明涉及包含西妥昔单抗(Cetuximab#+[�])的稳定的液体药物制剂，所述Cetuximab#+[�]是一种抗表皮生长因子受体(EGF受体)的嵌合单克隆抗体。所述制剂的贮藏稳定性增强并且可经胃肠外途径用于治疗肿瘤。 The invention relates to a stable liquid pharmaceutical formulation comprising Cetuximab(R), a chimeric monoclonal antibody against the receptor of endothelial growth factor (EGF receptor). The formulation has increased storage stability and can be used parenterally for the treatment of tumours.